Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy
Authors:
- 9 September 2023
- journal article
- research article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 41 (11) , 458.e1-458.e7
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Phase II Trial of Intravesical Nanoparticle Albumin Bound Paclitaxel for the Treatment of Nonmuscle Invasive Urothelial Carcinoma of the Bladder after bacillus Calmette-Guérin Treatment FailureJournal of Urology, 2014
- Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladderTherapeutic Advances in Urology, 2014
- Recurrence of high‐risk bladder cancer: A population‐based analysisCancer, 2013
- Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin TherapyJournal of Urology, 2013
- Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic ReviewEuropean Urology, 2011
- Prevention and Management of Complications Following Radical Cystectomy for Bladder CancerEuropean Urology, 2010
- Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting MethodologyEuropean Urology, 2009
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006
- Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treament With Gemcitabine Followed by Docetaxel in the Treatment of SarcomaJournal of Clinical Oncology, 2004
- Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancerSeminars in Oncology, 2001